Non-Hodgkin Lymphoma

Benefits of chimeric antigen receptor T-cell therapy far outweigh the risks involved, including secondary T-cell malignancies, according to Peter Marks, MD, PhD, director of the FDA’s Center for Biologic Evaluation and Research.

Patients with Merkel cell carcinoma have an increased risk for developing subsequent primary solid tumors and hematologic malignancies, according to data published in JAMA Dermatology.

A small study showed no impact from troponin-guided carvedilol and candesartan intervention to preserve cardiac function among seemingly high-risk patients undergoing chemotherapy.

An investigational chimeric antigen receptor T-cell therapy induced responses among patients with indolent lymphomas, according to topline data released by the agent’s manufacturer.

More than 80% of a cohort of adults with relapsed or refractory follicular lymphoma exhibited an overall response to subcutaneously administered epcoritamab-bysp, according to topline data from the agent’s manufacturer.

Ten of 11 patients with relapsed or refractory B-cell lymphoma achieved objective response to an investigational dual-target chimeric antigen receptor T-cell therapy, according to study results.

Individuals living with HIV historically have been at higher risk for non-Hodgkin lymphoma.

The FDA announced several regulatory actions the past few weeks.

NEW ORLEANS — Looking at 185 countries, a projection presented at the ASH Annual Meeting and Exhibition suggests the global burden of non-Hodgkin lymphoma will increase by 778,000 cases by 2040.

A risk model based on low-pass whole-genome sequencing of cell-free DNA predicted which patients are more likely to respond to chimeric antigen receptor T-cell therapy for large B-cell lymphoma, study results showed.